NCT02318667View on ClinicalTrials.gov

Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 27, 2015

Primary Completion Date

June 21, 2017

Study Completion Date

September 5, 2017

Conditions
Colitis, Ulcerative
Interventions
BIOLOGICAL

Golimumab

Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02318667 - Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). | Biotech Hunter | Biotech Hunter